제한항균제 전산 관리 프로그램 도입 전과 후의 반코마이신 사용 평가 = Evaluation of Vancomycin Use before and after the Computerized Restricted Antibiotic Control Program

다국어 초록 (Multilingual Abstract)

Since 2006, the Computerized Restricted Antibiotic Control Program (CRACP) has been incorporated to facilitate a more efficient approval process of vancomycin use at the Chonbuk National University Hospital. The purposes of the study were to evaluate proper use of vancomycin and to examine if there is any improvement when administering the CRACP. The use of vancomycin was retrospectively reviewed by a medical record review based on the American Society of Hospital Pharmacists (ASHP) criteria (i.e., indication, use of critical process indicators and use of outcome measurements) and compared before (Group I) and after the CRACP (Group II). Two hundred fifty six patient records were evaluated (138 in Group I and 118 in Group II). There was a statistically significant improvement in the report of justification for vancomycin use after CRACP (42.0% vs. 62.7%, p=0.001). Out of eight critical process indicators, two indicators (appropriate cultures prior to medication [68.8% vs. 85.6%, p=0.002] and serum vancomycin level measurement [0% vs. 7.6%, p=0.001]) were significantly improved after CRACP. The total incidence of adverse effects was decreased from 14.5% to 6.8%. In addition, there was a statistically significant difference in WBC count reduction within normal range (52.8% vs. 73.1%, p=0.024). The CRACP appears to be a promising approach to improve use of vacomycin in a hospital setting. However, further evaluation for the long-term period should be performed to confirm the performance of the program.

참고문헌 (Reference)

1 Johnson, C. C, "Viridans streptococci, Groups C and G streptococci, and Gemella morbillorum. In: Mandell, G. L., Bennett, J. E. and Dolin, R., eds. Principles and practice of infectious diseases. 6th ed. Vol 2" 2005 2434-,

2 Reginald, F, "Vancomycin, in Clinical pharmacokinetics. 3rd ed." the American Society of Health- System Pharmacists Inc. 349-, 2005

3 Mccormick, M. H, "Vancomycin, a new antibiotic. I. Chemical and biologic properties" 3 : 606-, 1956

4 Ambrose, P. J, "Vancomycin, In: Michael E. Winter. Basic Clinical Pharmacolinetics. 4th Ed" Lippincott Williams & Wilkins 451-, 2004

5 Cook, F. V, "Vancomycin revisited" 88 : 813-, 1978

6 Fekety, R, "Vancomycin" 66 : 175-, 1982

7 Kucers, A, "The Use of Antibiotics. A clinical Review of Antibacterial, Antifungal and Antiviral Drugs. Fifth ed." Oxford Univ Press 761-, 1977

8 Davis, R. L., "The "red man's syndrome" and slow infusion of vancomycin" 104 : 285-, 1986

9 Pfeiffer, R. R, "Structural features of vancomycin" 3 : 205-, 1981

10 CDC, "Staphylococcus areus resistant to vancomycin---United States, 2002" 51 : 565-, 2002

11 Khurana, C, "Red-man syndrome after vancomycin: potential cross-reactivity with teicoplanin" 75 : 41-, 1999

12 CDC, "Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)" 44 : 1-, 1995

13 Moellering, R. C, "Pharmacokinetics of vancomycin" 14 : 43-, 1984

14 Elting, L. S., "Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice" 83 : 2597-, 1998

15 Kunin, C. M, "Guidelines for peer review. Veterans Administration Ad Hoc Interdisciplinary Advisory Committee on Antimicrobial Usage. Audits of antimicrobial usage" 237 : 1001-, 1977

16 Cunha, B. A, "Clinical usefulness of vancomycin" 2 : 417-, 1983

17 Iwamoto, T, "Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin" 26 : 876-, 2003

18 Gerald, K. McEvoy, "AHFS drug information 2006" American Society of Hospital Pharmacists, Inc. 473-, 2006

19 Hughes, W. T, "1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America" 25 : 551-, 1977